Addition of Radiation Therapy to Surgery Nearly Doubles Survival of Rectal Cancer Patients

Publication
Article
OncologyONCOLOGY Vol 9 No 7
Volume 9
Issue 7

adiation therapy before surgery increases survival without increasing long-term complications for patients with rectal cancer, according to a 10-year study at Tufts University presented at the recent meeting of the American Radium Society. Resection

adiation therapy before surgery increases survival without increasinglong-term complications for patients with rectal cancer, accordingto a 10-year study at Tufts University presented at the recentmeeting of the American Radium Society. Resection alone was thestandard treatment for these patients when the study began in1972.

The overall 10-year survival rate for patients treated with radiationtherapy plus resection was 74%, said Dr. William P. Reed, Professorof Surgery at Tufts University School of Medicine at the WesternCampus in Springfield, Massachusetts. The 10-year survival ratewas 41% for patients who underwent resection alone, he said.

"The patients who had their tumor completely removed (about75% of the 149 patients), had even better survival rates, Dr.Reed told the American Radium Society at its annual meeting inParis. The 10-year survival rate for patients in this subgroupwas 80% for those treated with radiation and surgery, and 45%for those treated with surgery alone, he said.

In addition, patients who had radiation therapy were about a thirdless likely to have their disease return locally, compared topatients treated by surgery alone, according to Dr. Reed.

Physicians have been reluctant to treat these patients with full-doseradiation therapy before surgery because they were concerned thatadditional complications could occur, said Dr. Reed, who is alsoDirector of Surgical Oncology at Baystate Medical Center in Springfield.The study found that long-term complications from radiation therapywere minimal,he said.

Recent Videos
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
2 experts in this video
Related Content